A liquid chromatographic (LC) method with 2 detection systems for determining atropine (hyoscyamine) sulfate in commercial products was tested in a multilaboratory study. Depending on the type of product, sample solutions are prepared in methanol or methanol-water (1 + 1). The standard solution contains about 1.0 mg atropine sulfate/100 mL and is prepared in the same solvent used in sample preparation. LC separations are performed on a 7.5 cm Novapak silica column. The mobile phase is prepared by mixing 970 mL methanol with 30 mL of a 1% aqueous solution of 1-pentanesulfonic acid, sodium salt. Detection is by 2 systems, UV absorbance detection at 220 nm and fluorescence detection with excitation at 255 nm and emission at 285 nm. The injection volume is 100 or 200 mL. The following materials were used for the study: 2 separate samples of tablets labeled to contain 0.4 mg atropine sulfate, 2 separate samples of extended-release tablets labeled to contain 0.375 mg hyoscyamine sulfate, one sample of atropine sulfate injection labeled to contain 2 mg/mL, and one sample of 1% (v/v) atropine sulfate ophthalmic. Eight participants analyzed 2 separate portions of the 6 samples by both detection systems. A ninth participant analyzed the samples in duplicate but only by UV absorbance detection because of the unavailability of a fluorescence detector. The relative standard deviation (RSD) between laboratories ranged from 1.4 to 3.3% for samples of tablets and injections but higher for ophthalmic solutions (5.1-5.2%). A linearity study was conducted in the originating laboratory before the multilaboratory study with 5 solutions ranging in concentration from 0.80 to 1.20 mg atropine sulfate in 100 mL. Average recoveries were 100.0% by UV absorbance detection and 99.9% by fluorescence detection; the RSDs were 1.1 and 1.2%, respectively.
A tropine (D-L hyoscyamine) and L-hyoscyamine are the principal active constituents of Atropa belladonna, which also generally contains much smaller amounts of scopolamine (1) . The same alkaloids in approximately the same ratios are found in Datura stramonium (1) . Greater quantities of scopolamine are found in Hyoscyamus niger and Scopola carniolica (1) . Belladonna alkaloids are used as anticholinergic, antimuscarinic, antispasmodic, and mydriatic agents (1) . Although different and sometimes contrasting claims have been made, it is generally believed that the therapeutic properties of belladonna alkaloids depend exclusively or primarily on the levo isomers, L-hyoscyamine or L-scopolamine (1) . If this assumption is correct, hyoscyamine, which is 100% levo, is twice as potent as atropine, which is composed of approximately equal amounts of the D and L isomers. It has been claimed that atropine does not exist as such in plants, but that L-hyoscyamine, present in plants, undergoes racemization to atropine during the extraction process (2) . Several commercial preparations, such as tablets, injections, and solutions, contain atropine or hyoscyamine generally as the readily soluble sulfate salt; the most common adult dosage is 0.4 mg. Scopolamine, generally as the readily soluble hydrobromide salt, is much less common in commercial preparations; the most common adult dosage level is also 0.4 mg.
Occasionally a product is labeled to contain all 3 alkaloids, atropine sulfate, hyoscyamine sulfate, and scopolamine hydrobromide.
Published methods for the analysis of products containing belladonna alkaloids by gas liquid chromatography (GLC) or liquid chromatography (LC) generally obtain a separate chromatographic peak for scopolamine, but atropine and hyoscyamine form a single chromatographic peak. The U.S. Pharmacopeia (USP) has several monographs in which the alkaloid is analyzed by GC (3) . For the assay of atropine sulfate injections, the USP uses LC with a reversed-phase C18 column and UV absorbance detection at 254 nm (4) . For some products also containing diphenoxylate HCl the USP determines atropine sulfate by LC with a reversed-phase C18 column and UV absorbance detection at 206 nm (5). Ting (6) reported a method for the simultaneous determination of scopolamine, hyoscyamine, and phenobarbital in tablets with a reversed-phase C18 column and UV absorbance detection at 220 nm. In an earlier publication for the determination of atropine (hyoscyamine), Cieri (7) also used a reversed-phase C18 column, but fluorescence detection was used with excitation at 255 nm and emission at 285 nm. More recent experimentation in this laboratory indicated that a short-normal phase (silica) column is a valid alternative in the LC determination of belladonna alkaloids. The advantage of this column over some of those previously proposed is that it reaches equilibrium very quickly and remains stable for a long time. The mobile phase chosen is similar to those of previously reported LC methods (4-7) but requires smaller quantities of salt in the aqueous portion. As with the methods reviewed (4-7), atropine and hyoscyamine are not separated and form a single chromatographic peak. Scopolamine elutes earlier and, if present, is well separated from the combined atropine-hyoscyamine peak. The samples selected for this study, however, do not or should not contain scopolamine.
UV absorbance detection at 220 nm, as previously described by Ting (6) , and fluorescence detection with 255 nm excitation and 285 nm emission, as reported previously (7), are used.
Multilaboratory Study
Materials analyzed in this study were 2 separate samples of tablets labeled to contain 0.4 mg atropine sulfate, 2 separate samples of extended-release tablets labeled to contain 0.375 mg hyoscyamine sulfate, one sample of atropine sulfate injection labeled to contain 2 mg/mL, and one sample of 1% (w/v) atropine sulfate ophthalmic solution. The 2 samples of atropine sulfate tablets were obtained from 2 different manufacturers; the samples of hyoscyamine sulfate were from the same manufacturer but had different lot numbers. For each of the 4 samples of tablets, a 100 tablet composite was prepared, the average weight was calculated, and the tablets were ground to a uniform powder. Portions of each composite were placed in plastic vials identified with a sample number, and the vials were capped. For the liquid samples, portions were transferred to plastic bottles equipped with stoppers. The bottles were well stoppered and identified with a sample number.
Participants were instructed to analyze 2 separate portions of the 6 samples submitted. Although only 2 determinations were required for each sample, quantities supplied were more than sufficient for ³3 determinations. In addition to the samples, each participant was supplied with the reference materials needed, a copy of the method, and instructions containing other necessary data.
All the samples, both liquid and solid, had been analyzed by the originator of the method shortly after receipt and again 3 months later. Results were approximately the same, and variations were not more than expected in replicate determinations. All the samples were also analyzed by another analyst in the originating laboratory according to the same protocol later followed in other laboratories. 
METHOD

Apparatus and Reagents
Sample Preparations
(a) Normal-release tablets (generally atropine sulfate).-Weigh ³20 tablets, calculate average weight, and grind to uniform powder. Accurately weigh portion of ground composite, estimated to contain 0.5 mg active ingredient, and transfer to a 50 mL volumetric flask. Add 25 mL diluted methanol, stopper flask, and shake flask vigorously for 2 min.
Place flask in water bath at 50°C for 10 min, and swirl flask occasionally. Remove flask from bath, cool to room temperature, dilute to volume with diluted methanol, stopper flask, and mix contents. Filter solution through fast-speed paper, discarding first 5 mL.
(b) Extended-release tablets (generally hyoscyamine sulfate).-Proceed as in (a), but use methanol as the solvent.
(c) Injections and solutions.-Pipet 1.0 or 2.0 mL into a 100 mL volumetric flask, dilute to volume with methanol, stopper flask, and mix contents. Make further dilutions, if necessary, so that the concentration of the alkaloid is about 1 mg/100 mL methanol.
LC Determination
Arrange the LC system with the 2 detectors in series. If this is not possible or not desired, use 2 separate systems, one for each detector. Inject 100 or 200 mL by using a Rheodyne or other suitable injection system. Equilibrate column with mobile phase at a flow rate of 1.5 mL/min for ³30 min. Set UV absorbance detector at 220 nm and fluorescence detector at 255 nm excitation and 285 nm emission.
Inject aliquot of system suitability solution. Scopolamine elutes after 1-2 min; atropine, after 2-4 min (Figure 1 ). Resolution of the 2 peaks should be ³2.0. If elution and separation of the peaks are not adequate, change flow rate or make some adjustments in the composition of the mobile phase. One possible adjustment is to increase or decrease by a few milliliters the volume of salt solution in the mobile phase. Another possibility is to change the concentration of reagent, which should be £1.5 g/100 mL salt solution. Adjust sensitivities of both detectors so that the peak height of atropine is 70-80% of chart height. Inject 4 consecutive aliquots of the standard solution. The relative standard deviation (RSD) of the peak responses should not be >2.5%.
Inject 2 aliquots of the standard solution, 3 aliquots of the sample solution, and 2 more aliquots of the standard solution. Measure the peak response of the atropine (hyoscyamine) in each chromatogram.
Designate as Ru the average peak response in the 3 sample chromatograms, and designate as Rs the average peak response in the 4 standard chromatograms.
Calculate the amount of atropine (hyoscyamine) sulfate in the sample solution by the formula (Ru)(C) (1 -M/100)(V)(1.0266)/(Rs) where C = mg atropine sulfate/mL standard solution, M = % water in atropine sulfate standard, and V = volume of sample solution (mL). The factor 1.0266 converts atropine (hyoscyamine) to the monohydrate.
Linearity Study
Prepare 5 solutions containing atropine sulfate at concentrations of 0.8-1.2 mg/100 mL. Inject 100 mL and subsequently 200 mL of each solution. Calculate amount of atropine sulfate in each solution, and determine recovery by the formula: (amount found)(100)/amount present. Values reported (Table 1 ) are the average of 2 determinations, one using 100 mL and the other, 200 mL, for injection.
Results and Discussion
The atropine sulfate used for reference was from a bottle purchased from Sigma (Product No. A 0257) and containing 25 g, of which about 800 mg in a sealed vial was sent to each of the collaborators. The material was analyzed in this laboratory for water content and assayed according to the USP method for this product. Water content found was 3.2%, and the assay result was 99.8%, on an anhydrous basis. The participants did not reassay the material but, as requested, deter- mined the water content titrimetrically at the time of use according to the USP procedure. Water content results by the participants varied from 3.5 to 4.4% with an average of 3.8%. The increase and variability of the water content after the initial determination are due primarily to the hygroscopic nature of the atropine sulfate. The water content of the atropine sulfate reference as determined at the time of use by each analyst is later included in the calculation of sample results. Scopolamine was also obtained from Sigma (Product No. S 0929) but was not assayed because the material was used only to establish adequate separation of peaks and was not present in the standard solution. Solvents considered for standard and sample preparations were methanol, water, and methanol-water (1 + 1).
The reference materials atropine sulfate and scopolamine hydrobromide could be readily dissolved in any of the 3 solvents. Under the LC conditions of this investigation, methanol is preferable because peak tailing is slightly less. Methanol, however, did not adequately extract the alkaloids from the 2 powdered samples of atropine sulfate tablets included in this study. For these 2 samples, diluted methanol, i.e., methanol-water (1 + 1) was found to be a satisfactory solvent. Other samples of atropine sulfate tablets were not available when this investigation started; it cannot be said with certainty whether this extracting difficulty with methanol is a characteristic of all samples of atropine sulfate or is limited to these 2 samples. Powdered samples of extended-release tablets are extracted well with methanol, whereas water and diluted methanol are not suitable solvents because of the formation of a A = UV absorbance detection at 220 nm; B = fluorescence detection with excitation at 255 nm and emission at 285 nm; S1 and S2 = 2 different samples of tablets labeled to contain 0.4 mg atropine sulfate; S3 and S4 = 2 different samples of extended-release tablets labeled to contain 0.375 mg hyoscyamine sulfate; S5 = sample of atropine sulfate injection labeled to contain 2 mg/mL; and S6 = sample of 1% (w/v) sample of atropine sulfate ophthalmic solution. b Replicate determinations by the same analyst, using 2 separate sample solutions. c n = 18. d As defined in Table 1 . e n = 16. a gel. Water could be used as the solvent if the extended-release tablets are not ground, but the extraction is much less effective. The weighed portions of the ground samples are transferred to a volumetric flask and extracted with a volume of the appropriate solvent equal to about half the nominal volume of the flask, which is the placed in water bath at 50°C for 10 min. The mixture is cooled, diluted to volume, and filtered. Heating the mixture ensures complete extraction and does not cause degradation of the active ingredients. Standard and sample solutions are stable for several days, but it is generally desirable to analyze them shortly after preparation. For liquid samples, such as injections and solutions, all 3 solvents previously indicated are suitable for any required dilutions, but methanol is preferred because it generally yields better chromatographic peaks, as indicated earlier.
As mentioned in the introduction, atropine sulfate is detected and quantitated at 254 nm in the USP monograph for injections (4) . However, the absorptivity of this compound is rather weak at 254 nm, and as a result determinations at this wavelenghth are generally not possible or not indicated for tablets, because the amount of the active ingredient is generally very small and also because of possible interferences from excipients. The absorptivity of atropine (hyoscyamine) sulfate is much greater at lower wavelengths (205-230 nm), and quantitation in this wavelength range is generally satisfactory for the analysis of tablets. With a fluorescence detector it is possible to use 255 nm for excitation even for the analysis of tablets because there is no interference from the excipients.
The tablets analyzed in this study contain about 0.4 mg of the active ingredients; some commercial samples of tablets contain even smaller quantities. To ensure complete extraction of the drug, an amount of powder equivalent to a tablet requires ³50 mL. Because concentration of the active ingredient is low, injection volume for LC analysis must be ³100 mL. The participants in this study were given the choice of injecting 100 or 200 mL, but obviously the same volumes of the standard and sample solutions must be injected. Most participants elected to inject 200 mL, but some injected 100 mL. With samples of injections it may sometimes be possible to change the concentrations of the active ingredients in solutions and inject smaller volumes but for the sake of uniformity, in this study the same procedure was followed for tablets and injections. Figure 1 shows chromatograms obtained by both detection systems for the system suitability solution, a standard solution, and a sample solution of atropine sulfate, all in diluted methanol. There are no peaks in the blank chromatograms, obtained by both detection systems, at the retention time of scopolamine or atropine. Solvent and excipient peaks are larger by UV detection. Chromatograms of methanolic solutions are very similar to those shown.
Atropine sulfate is used the as reference standard for the analysis of all the samples, including those declaring the ac- a S1, S2, S3, S4, S5, and S6 are as defined in Table 2 . b A and B, as defined in Table 2 . tive ingredient as hyoscyamine sulfate. These 2 compounds have the same chemical formula, differing only in stereo configuration, and they have the same chromatographic behavior and response. Results found as percentages of the labeled amounts of atropine (hyoscyamine) sulfate monohydrate are reported in Table 2 . Duplicate determinations were made by weighing or pipetting separate portions of each of the 6 samples analyzed. The nature and type of samples used in the study were such that it appeared difficult or extremely difficult to prepare truly blind duplicates. Eight participants made duplicate determinations with both detection systems; a ninth participant analyzed the same samples also in duplicate with UV absorbance detection only. Participants 1-6 arranged the detectors in series; participants 7 and 8 used one detector at a time, but the solutions injected were the same for both systems. The averages and the corresponding RSD values were calculated for each of the 2 sets of 8 or 9 individual results in different laboratories. With the exception of sample S6, the RSD values were always £3.3% with both detection systems. For sample S6 (ophthalmic solution) RSD values were about 5%; the lower reproducibility in this instance was probably due to the fact that the sample was rather viscous and probably not too uniform. Better reproducibility might be obtained by taking a larger volume of the ophthalmic solution for analysis, but the amount of material available was not sufficient to do so. When the detectors were arranged in series (participants 1-6) agreement was generally very good between A (UV absorbance detection) and B (fluorescence detection). When the detectors were used separately (participants 7and 8) agreement between the 2 results was slightly lower.
The results indicate that the 2 detection systems are equivalent in sensitivity, reproducibility, and accuracy. Fluorescence detection may be preferable for some samples to minimize possible interferences from excipients and any other active ingredients, if present. Whenever possible it is advisable to use a system that permits the simultaneous use of the 2 detectors. A considerable discrepancy between the 2 results may be a possible indication of interferences with one of the systems. Table 3 reports, for each sample preparation, the average results of 2 determinations, one by UV absorbance detection and one by fluorescence detection. The RSDs (indicated as R in the table), calculated for each set of 2 results, varied from 0 (no difference) to a maximum of 5.6%. For each sample the average of the 6 individual R values was also calculated. Table 4 compares the results obtained by each participant with both detection systems for 2 different solutions of the same product. The average result and the corresponding RSD were calculated for each set of 2 results obtained with each detection system. Average RSDs ranged from 0.7 to 2.1% with UV absorbance detection (average of 9 RSDs) and from 0.3 to 2.2% with fluorescence detection (average of 8 RSDs). The reproducibility, which in this case depended on the nature of the sample, was the best for (injections), the worst for S6 (ophthalmic solutions), and intermediate for the samples of tablets.
The study participant in the Philadelphia District used the same column used by the originator of the method; all the other participants used a column that was already in their possession or was purchased for the study. All participants met the specified requirements for resolution and standard deviation of responses of replicate injections. They also reported that the columns performed very well over long periods of time and were not deteriorated by the salt present in the mobile phase.
The method does not present serious hazards, but precautions must be used when alkaloids are weighed and handled because they are highly toxic.
